Weekly Funding Opportunities

[Med Research]

Greenwall Foundation: Making a Difference in Real-World Bioethics Dilemmas<https://urldefense.proofpoint.com/v2/url?u=https-3A__greenwall.org_making-2Da-2Ddifference-2Dcurrent-2Drequest-2Dfor-2Dproposals.php&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=6nIaJt9bstrS2ARJKZbls8lAPScG9-fFrOmKHNPQSZE&e= >
The Greenwall Foundation will support research to help resolve an important emerging or unanswered bioethics problem in clinical, biomedical, or public health decision-making, policy, or practice. The Foundation’s vision is to make bioethics integral to decisions in health care, policy, and research. Our mission is to expand bioethics knowledge to improve clinical, biomedical, and public health decision-making, policy, and practice. Projects funded under the Making a Difference program should promote the Foundation’s vision and mission through innovative bioethics research that will have a real-world, practical impact.
While we welcome all innovative proposals that will have a real-world impact, we are particularly interested in proposals that address the ethical and policy issues raised by the following priority topics:

  *   Developments in artificial intelligence;

  *   Responses to the opioid epidemic;

  *   Bias and discrimination in clinical care against patients or clinicians, based on a broad range of characteristics;

  *   Advances in biomedical and clinical research and their translation into clinical practice; and

  *   Healthcare access, costs, and resource allocation.
Proposals for projects that address other real-world, practical bioethics problems are also welcome.
Letter of intent due July 1, 2019.  Med-RA deadline to review the on-line LOI is June 24.

Robert Wood Johnson Foundation:  Using Managed Care Payment and Contracting Strategies to Address Medicaid Enrollees’ Social Needs<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.rwjf.org_en_library_funding-2Dopportunities_2019_research-2Din-2Dtransforming-2Dhealth-2Dand-2Dhealth-2Dcare-2Dsystems.html-3Frid-3D0034400001rm2ZLAAY-26et-5Fcid-3D1742132&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=SpI8Iq3iWP9iCJKl4bgm7n-NQQcoCaskQIoUM7Mviww&e= >
This call for proposals seeks to fund research studies that examine how state Medicaid programs are using managed care payment and contracting strategies to address enrollees’ social needs; the ways MCOs are responding; and the effect of these activities on enrollees, plans, community-based organizations, and other stakeholders. We strongly encourage applicants to consider how these activities affect health equity, meaning that everyone has a fair and just opportunity to be as healthy as possible. The goal of this funding opportunity is to generate timely evidence on the experiences of states, MCOs, Medicaid enrollees, and community-based organizations in order to inform future decision-making by state and federal policymakers and other key stakeholders.
Letter of intent due July 2, 2019. Med-RA deadline to receive draft documents: June 25.

Alzheimer’s Drug Discovery Foundation: Prevention Beyond the Pipeline<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.alzdiscovery.org_research-2Dand-2Dgrants_funding-2Dopportunities_prevention-2Dbeyond-2Dthe-2Dpipeline&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=OHEtT6i7y3TwmhToR_fAyhnFY1eQX4uJ-LIskP-JUFI&e= >
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Funding priorities: Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. More information here. More information here<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.alzdiscovery.org_research-2Dand-2Dgrants_funding-2Dopportunities_capa-2Dconsortium&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=bRs1SqQDatRJCthta2C8sgk_6q7DhggQQDxBPWgNwp4&e= >. Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer’s or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see Box 1 in the ADDF 2016 position paper<https://urldefense.proofpoint.com/v2/url?u=https-3A__alzres.biomedcentral.com_articles_10.1186_s13195-2D016-2D0200-2D3&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=JNYlw_Ohvz6UEKVSvukJYcKjadzg6MOupc3xn6Zo7xA&e= >). Methods may include randomized trials or epidemiology. Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.
Average Duration: One year for epidemiological analyses. Varies (multi-year) for clinical trials.
Average Award: $50,000-$100,000 for epidemiological analyses based on scope of research. Up to $3 million for clinical trials based on stage and scope of research.
Letter of intent due July 12, 2019 and October 11, 2019. Med-RA deadline to receive draft documents for July deadline: July 1.

Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D289.html&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=wg7yQvczH62rVNuPeEQBOhrKW6HXsppw_kZb87qwFuY&e= >
The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses.
The objectives of the FOA will be accomplished by supporting basic and translational neuroscientists who are committed to improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. As such, this FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.
Standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for October deadline: September 23.

American Heart Association: Collaborative Sciences Award<https://urldefense.proofpoint.com/v2/url?u=https-3A__professional.heart.org_professional_ResearchPrograms_UCM-5F460459-5FCollaborative-2DSciences-2DAward.jsp&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=PmBZ-1cJ2exFnKWOZ4221NROKdY5xwpUZVpKkRm2jBQ&e= >
Science Focus: Multidisciplinary research broadly related to cardiovascular function, cardiovascular disease, and stroke, or to related clinical, basic science, bioengineering, biotechnology, or public health problems.
The proposal must focus on the collaborative relationship, such that the scientific objectives could not be achieved without the efforts of at least two co-principal investigators and their respective disciplines. The combination and integration of studies may be inclusive of basic, clinical, population, behavioral, and/or translational research. Projects must include at least one Co-PI from a field outside cardiovascular disease and stroke. This award is also intended to foster collaboration between established and early- or mid-career investigators. Applications by existing collaborators are permitted, provided that the proposal is for a new and novel idea or approach that has not been funded before.
$250,000 per year for 3-year projects, 10% IDC.
Letter of intent due October 8, 2019. Med-RA deadline to receive draft documents: September 25.

Pfizer 2019 Global Breast Cancer Competitive Grant Research Program<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.pfizer.com_sites_default_files_GMG-5FResearch-5F2019ONC3.pdf&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=GXSpEkPt4vLJmvJLgH7fTdgBQ0o-ekKOkw71McxPazw&e= >
The intent of this Request for Proposal (RFP) is to invite investigators from across the globe to submit innovative research proposals focusing in the following areas.
In hormone receptor positive metastatic breast cancer:

  *   Treatment strategies to overcome palbociclib + endocrine treatment resistance
  *   Novel treatment concepts of adding immuno-oncology (IO) agents to palbociclib + endocrine therapy
In metastatic breast cancer:

  *   Novel treatment strategies utilizing talazoparib beyond gBRCA mutation
  *   Novel treatment strategies to overcome talazoparib resistance or improve tumor sensitization to talazoparib
In addition, incorporation of the following into the proposed clinical study would be of interest: a correlative/biomarker component using paired biopsy samples (e.g. pre- and post-treatment), cfDNA assessment, predictive signatures beyond gBRCAmut in advanced breast cancer (such as tumor BRCA/PALB2mut or HRD), or PK/PD biomarkers to explore potential mechanisms of resistance/response or synergistic effect.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.
$5M will be split across 6-8 projects of 1-2 years in duration, 28% IDC. Letter of intent due October 15, 2019. Med-RA deadline to receive draft documents: October 1.

Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (R61 / R33 – Clinical Trial Not Allowed)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DDA-2D20-2D019.html&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=7lvu7VswQCOsT2Ro9S8MWmKTjwwVUJRCpaLnXNayBYo&e= >
This funding opportunity aims to support the development and the application of novel pharmacological approaches to manipulate signaling mediated by endogenous opioid receptors in defined circuits, cell-types or subcellular compartments in live organisms.
Due October 17, 2019. Med-RA deadline to receive draft documents: October 3.

Interpersonal Processes in Alzheimer’s Disease and Related Dementias Clinical Interactions and Care Partnerships (R01 Clinical Trial Optional)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAG-2D20-2D006.html&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=JBpxK2KUq0N9imI8EQVyQxN9jS83QTXSqPP7s0kT2uU&e= >
This Funding Opportunity Announcement (FOA) invites applications focused on interpersonal processes in the context of triadic interactions in clinical contexts involving caregivers, individuals with Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD), and health care practitioners and the impact of those processes on patient outcomes. The goal of this initiative is to support research that can lead to the development of interventions for optimizing communication among patients, caregivers, and healthcare practitioners and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD. To these ends, basic research and translational research is solicited in two high-priority areas: (1) effective communications and relationships among patients, healthcare practitioners, and caregivers; and (2) associations between close relationship processes and health in caregiving relationships.
Due October 23, 2019. Med-RA deadline to receive draft documents: October 9.

Brain Initiative: Research to Develop and Validate Advanced Human Cell-Based Assays To Model Brain Structure and Function (R01 Clinical Trial Not Allowed)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DMH-2D20-2D140.html&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=qWDEM2jxLkr6hBXKju0ClNJpk9g696tOAVwf_UZoNPE&e= >
This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. This includes technologies that do not rely on the use of human fetal tissue, as described in NOT-OD-19-042<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_notice-2Dfiles_NOT-2DOD-2D19-2D042.html&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=3o6hCopORPEjXui4i-w3XQneDSV0zPQJV8eKv5yRyPw&s=dsvCKvl4dGIxgbonj_X4vjhKLZJoEs8IGdvHF0vUKPc&e= >. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.
Due November 1, 2019. Med-RA deadline to receive draft documents: October 18.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20190606/ede4a28d/attachment.html>